China’s 2026 NRDL Drives Major Breakthroughs in Drug Access
China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the … Read more
